X0306 4 2022-11-29 0 0001840574 Verve Therapeutics, Inc. VERV 0001625110 Dorval Allison C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 0 1 0 0 Chief Financial Officer Common Stock 2022-11-29 4 M 0 1875 A 2740 D Common Stock 2022-11-29 4 S 0 554 22.10 D 2186 D Restricted Stock Units 2022-11-29 4 M 0 1875 0.00 D Common Stock 1875 5625 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Includes 865 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan. Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on November 29, 2022. This sale does not represent a discretionary trade by the reporting person. On November 29, 2021, the reporting person was granted 7,500 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on November 29, 2022 and the remainder vesting in equal annual installments until November 29, 2025. /s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval 2022-12-01